415 related articles for article (PubMed ID: 7724569)
1. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.
Facci L; Dal Toso R; Romanello S; Buriani A; Skaper SD; Leon A
Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3376-80. PubMed ID: 7724569
[TBL] [Abstract][Full Text] [Related]
2. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons.
Skaper SD; Buriani A; Dal Toso R; Petrelli L; Romanello S; Facci L; Leon A
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):3984-9. PubMed ID: 8633002
[TBL] [Abstract][Full Text] [Related]
3. Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells.
Lau AH; Chow SS
Eur J Pharmacol; 2003 Mar; 464(2-3):229-35. PubMed ID: 12620517
[TBL] [Abstract][Full Text] [Related]
4. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain.
Jaggar SI; Hasnie FS; Sellaturay S; Rice AS
Pain; 1998 May; 76(1-2):189-99. PubMed ID: 9696473
[TBL] [Abstract][Full Text] [Related]
5. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder.
Jaggar SI; Sellaturay S; Rice AS
Neurosci Lett; 1998 Sep; 253(2):123-6. PubMed ID: 9774165
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors.
Farquhar-Smith WP; Jaggar SI; Rice AS
Pain; 2002 May; 97(1-2):11-21. PubMed ID: 12031775
[TBL] [Abstract][Full Text] [Related]
7. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder.
Farquhar-Smith WP; Rice AS
Anesthesiology; 2001 Mar; 94(3):507-13; discussion 6A. PubMed ID: 11374613
[TBL] [Abstract][Full Text] [Related]
8. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.
Sugiura T; Kondo S; Kishimoto S; Miyashita T; Nakane S; Kodaka T; Suhara Y; Takayama H; Waku K
J Biol Chem; 2000 Jan; 275(1):605-12. PubMed ID: 10617657
[TBL] [Abstract][Full Text] [Related]
9. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Romero TR; Resende LC; Guzzo LS; Duarte ID
Anesth Analg; 2013 Feb; 116(2):463-72. PubMed ID: 23302980
[TBL] [Abstract][Full Text] [Related]
10. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro.
Bueb JL; Lambert DM; Tschirhart EJ
Biochim Biophys Acta; 2001 Apr; 1538(2-3):252-9. PubMed ID: 11336796
[TBL] [Abstract][Full Text] [Related]
11. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
12. Control of pain initiation by endogenous cannabinoids.
Calignano A; La Rana G; Giuffrida A; Piomelli D
Nature; 1998 Jul; 394(6690):277-81. PubMed ID: 9685157
[TBL] [Abstract][Full Text] [Related]
13. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
14. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.
Mazzari S; Canella R; Petrelli L; Marcolongo G; Leon A
Eur J Pharmacol; 1996 Apr; 300(3):227-36. PubMed ID: 8739213
[TBL] [Abstract][Full Text] [Related]
15. The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery.
White R; Hiley CR
Br J Pharmacol; 1998 Oct; 125(3):533-41. PubMed ID: 9806337
[TBL] [Abstract][Full Text] [Related]
16. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide.
Jonsson KO; Vandevoorde S; Lambert DM; Tiger G; Fowler CJ
Br J Pharmacol; 2001 Aug; 133(8):1263-75. PubMed ID: 11498512
[TBL] [Abstract][Full Text] [Related]
17. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
18. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors.
Lambert DM; DiPaolo FG; Sonveaux P; Kanyonyo M; Govaerts SJ; Hermans E; Bueb J; Delzenne NM; Tschirhart EJ
Biochim Biophys Acta; 1999 Sep; 1440(2-3):266-74. PubMed ID: 10521710
[TBL] [Abstract][Full Text] [Related]
19. Anandamide inhibits FcεRI-dependent degranulation and cytokine synthesis in mast cells through CB
Cruz SL; Sánchez-Miranda E; Castillo-Arellano JI; Cervantes-Villagrana RD; Ibarra-Sánchez A; González-Espinosa C
Int Immunopharmacol; 2018 Nov; 64():298-307. PubMed ID: 30243065
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.
White R; Ho WS; Bottrill FE; Ford WR; Hiley CR
Br J Pharmacol; 2001 Oct; 134(4):921-9. PubMed ID: 11606334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
